Chemical Hair Relaxer Lawsuit: The Complete Guide

Chemical hair relaxer litigation alleges that long-term use of lye and no-lye straightening products increases the risk of uterine cancer, endometrial cancer, and ovarian cancer through exposure to endocrine-disrupting chemicals (EDCs) such as phthalates, parabens, and formaldehyde-releasing preservatives. Unlike a consumer refund class action, injury claims are typically filed as individual lawsuits coordinated in MDL No. 3060 (In re: Hair Relaxer Marketing, Sales Practices, and Products Liability Litigation). The litigation gained momentum after the NIH Sister Study analysis drew national attention to uterine cancer incidence among frequent users. Defendants have moved to challenge general causation and preemption under cosmetics law, while plaintiffs' leadership develops epidemiology and toxicology experts. As of mid-2026, the MDL remains in active pretrial proceedings with discovery, science hearings, and bellwether planning underway. Top Tier Legal publishes educational resources and may connect qualifying inquiries with independent law firms that handle hair relaxer inventories. We do not represent clients or predict outcomes.

The scientific debate centers on whether chemicals in relaxers disrupt hormone pathways and whether population studies show elevated rates of uterine and related cancers among frequent users. NIH Sister Study (2022) — Researchers analyzing data from more than 33,000 women reported an association between frequent hair straightener use and higher uterine cancer incidence. The finding generated widespread media coverage and plaintiff filings. Endocrine Disruptors — Relaxers may contain phthalates, parabens, and other EDCs that can mimic or interfere with estrogen signaling. Plaintiffs argue that scalp absorption and burn injuries increase uptake. Formaldehyde and Lye Formulations — Some products release formaldehyde or use sodium hydroxide (lye). Occupational and consumer exposure routes differ, but both appear in litigation narratives. Defense Arguments — Manufacturers contest causation, citing confounding factors (obesity, genetics, other chemical exposures) and arguing that cosmetics preemption limits failure-to-warn claims. Courts continue to rule on admissibility of expert testimony.